banter and General Discussion, page-11081

First 11081 Last

Share
Profile

Follow
Kerebrad

2,476 Posts.

479

30/09/24

07:00

Post #: 75896740
Share

Originally posted by Bazsa: ↑

A hope was supposed to come in 2019 after the Food and Drug Administration (FDA) approved Ruxolitinib (RUX), a JAK1/2 inhibitor, for therapy of SR-aGVHD in adult and pediatric patients > 12 years [4]. Approval was based on favourable results of REACH2 clinical trial in which RUX showed the advantage over other well-known immunosuppressive therapies. Promising response rate to RUX at day 28 was 62.3% when compared with 39.4% in control group (p < 0.001) [5].

Obviously Reach2 failed to demonstrate true response rates.

Expand

Bordering on criminal

Originally posted by reginaldp: ↑

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668796/

Off label use for Adult SR-RR-aGvHD Grade lll-lV would be, imo, immediate- look at the gobblegook re an already approved approved therapy
Patients and methods
This retrospective study included 18 patients treated with RUX as a salvage therapy for GIII–IV SR-aGVHD.

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ruxolitinib (RUX), an oral JAK1 and JAK2 inhibitor, has recently been approved for patients with SR-aGVHD. The aim of this study was to evaluate RUX efficacy and toxicity in a real-world setting. Eighteen patients received RUX at 5 mg or 10 mg twice a day after a median 3 lines of prior unsuccessful immunosuppressive therapy. Median time on RUX therapy was 28 days (range 7–129). Five patients (28%) responded to RUX, including 4 complete responses and 1 partial response. Response to RUX was irrespective of aGVHD grade and the number of involved organs. One-year overall survival (OS) was 60% for RUX-responders versus 31% for non-responders (p = ns). Treatment duration greater than 29.5 days was found to have a positive impact on OS (p < 0.007). Major adverse events during RUX treatment were grade 3–4 thrombocytopenia (61% of patients) and cytomegalovirus reactivation (50%). After median follow-up of 55 days (range 29–706), 14 patients (78%) died, mainly due to further progression of GVHD. RUX may represent a valuable therapeutic option for some patients with advanced SR-aGVHD, but more studies are warranted.

Valuable option?????????????????????????? almost all have left this earth in just 55 days....................

@stanjupiter Hi SJ, hopefully we can get a positive result this time around and a major shift in how our most vulnerable are treated. Thank-you for your ongoing , thoroughly researched posts on this forum.

Reg

Expand

Definitely bordering on criminal- shocking.

This 3rd CRL will test if FDA practice what they preach.

Any day now!!

MSB Price at posting: $1.13 Sentiment: Hold Disclosure: Held
6 Upvote

Reply

Top Stories

Making money: How many microcaps should be in an investor's portfolio?

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch